BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 34756755)

  • 21. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
    Muldermans JL; Romak LB; Kwon ED; Park SS; Olivier KR
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):696-702. PubMed ID: 27131082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeat stereotactic body radiotherapy for oligometastatic disease.
    Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
    Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
    Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
    Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
    Nagpal SK; Khabra K; Ross G; Kirby AM
    Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy of oligometastatic prostate cancer: a systematic review.
    Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
    Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
    Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
    Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
    Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
    Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
    Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
    Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes.
    Ursino S; Montrone S; Cantarella M; Menghini V; Matteucci F; Mazzotti V; Fiorica F; Fedele D; Erba P; Morganti R; Fabrini MG; Caramella D
    Tumori; 2016; 102(1):59-64. PubMed ID: 26439149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
    Pasqualetti F; Panichi M; Sainato A; Matteucci F; Galli L; Cocuzza P; Ferrazza P; Coraggio G; Pasqualetti G; Derosa L; Sollini M; Mannelli L; Ortori S; Monzani F; Ricci S; Greco C; Fabrini MG; Erba PA
    Radiat Oncol; 2016 Jan; 11():9. PubMed ID: 26796633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis.
    Deodato F; Pezzulla D; Cilla S; Ferro M; Romano C; Bonome P; Buwenge M; Zamagni A; Strigari L; Valentini V; Morganti AG; Macchia G
    Clin Transl Oncol; 2022 Jun; 24(6):1177-1183. PubMed ID: 34984604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.
    Ponti E; Ingrosso G; Carosi A; Di Murro L; Lancia A; Pietrasanta F; Santoni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):e279-e284. PubMed ID: 25604915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.